Business Wire
21 Sept 2026, 06:00 UTC · 2h ago
Verdict
Headline takes no side. We score PRTC +0.80 across two claims — strongly bullish.
+0.80strongly bullish
More positive than 83% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
The FDA granted Fast Track designation for LYT-200 in combination with a hypomethylating agent for relapsed/refractory high-risk myelodysplastic syndromes.
Newannounced today in press release dated 2026-09-21
More positive than 92% of claims this week
PureTech successfully completed its End-of-Phase 1 (EOP1) meeting with the U.S. FDA regarding LYT-200.
New
Continue reading
5 related stories
Scored by the NIS engine · methodology.
So whatSuccessful EOP1 clearance typically triggers the commencement of Phase 2 trials within the coming months.
More positive than 76% of claims this week
Which stocks this story touches
More positive than 83% of ticker scores this week
The company achieved a successful EOP1 meeting with the FDA and received Fast Track designation for its drug candidate LYT-200.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
8h ago
—
No price for PRTC right now — the quote feed didn't answer.
PRTC chart →
